BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 38849478)

  • 1. Machine learning for the identification of neoantigen-reactive CD8 + T cells in gastrointestinal cancer using single-cell sequencing.
    Sun H; Han X; Du Z; Chen G; Guo T; Xie F; Gu W; Shi Z
    Br J Cancer; 2024 Jun; ():. PubMed ID: 38849478
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cell surface marker-based capture of neoantigen-reactive CD8
    Chatani PD; Lowery FJ; Parikh NB; Hitscherich KJ; Yossef R; Hill V; Gartner JJ; Paria B; Florentin M; Ray S; Bera A; Parkhust M; Robbins P; Krishna S; Rosenberg SA
    J Immunother Cancer; 2023 May; 11(5):. PubMed ID: 37258038
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transcriptomic profiles of neoantigen-reactive T cells in human gastrointestinal cancers.
    Zheng C; Fass JN; Shih YP; Gunderson AJ; Sanjuan Silva N; Huang H; Bernard BM; Rajamanickam V; Slagel J; Bifulco CB; Piening B; Newell PHA; Hansen PD; Tran E
    Cancer Cell; 2022 Apr; 40(4):410-423.e7. PubMed ID: 35413272
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhanced detection of neoantigen-reactive T cells targeting unique and shared oncogenes for personalized cancer immunotherapy.
    Yossef R; Tran E; Deniger DC; Gros A; Pasetto A; Parkhurst MR; Gartner JJ; Prickett TD; Cafri G; Robbins PF; Rosenberg SA
    JCI Insight; 2018 Oct; 3(19):. PubMed ID: 30282837
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Direct identification of neoantigen-specific TCRs from tumor specimens by high-throughput single-cell sequencing.
    Lu YC; Zheng Z; Lowery FJ; Gartner JJ; Prickett TD; Robbins PF; Rosenberg SA
    J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34321276
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neoantigen-specific stimulation of tumor-infiltrating lymphocytes enables effective TCR isolation and expansion while preserving stem-like memory phenotypes.
    Levin N; Kim SP; Marquardt CA; Vale NR; Yu Z; Sindiri S; Gartner JJ; Parkhurst M; Krishna S; Lowery FJ; Zacharakis N; Levy L; Prickett TD; Benzine T; Ray S; Masi RV; Gasmi B; Li Y; Islam R; Bera A; Goff SL; Robbins PF; Rosenberg SA
    J Immunother Cancer; 2024 May; 12(5):. PubMed ID: 38816232
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neoantigen-specific immunity in low mutation burden colorectal cancers of the consensus molecular subtype 4.
    van den Bulk J; Verdegaal EME; Ruano D; Ijsselsteijn ME; Visser M; van der Breggen R; Duhen T; van der Ploeg M; de Vries NL; Oosting J; Peeters KCMJ; Weinberg AD; Farina-Sarasqueta A; van der Burg SH; de Miranda NFCC
    Genome Med; 2019 Dec; 11(1):87. PubMed ID: 31888734
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficient identification of neoantigen-specific T-cell responses in advanced human ovarian cancer.
    Liu S; Matsuzaki J; Wei L; Tsuji T; Battaglia S; Hu Q; Cortes E; Wong L; Yan L; Long M; Miliotto A; Bateman NW; Lele SB; Chodon T; Koya RC; Yao S; Zhu Q; Conrads TP; Wang J; Maxwell GL; Lugade AA; Odunsi K
    J Immunother Cancer; 2019 Jun; 7(1):156. PubMed ID: 31221207
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Checkpoint blockade immunotherapy reshapes the high-dimensional phenotypic heterogeneity of murine intratumoural neoantigen-specific CD8
    Fehlings M; Simoni Y; Penny HL; Becht E; Loh CY; Gubin MM; Ward JP; Wong SC; Schreiber RD; Newell EW
    Nat Commun; 2017 Sep; 8(1):562. PubMed ID: 28916749
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Late-differentiated effector neoantigen-specific CD8+ T cells are enriched in peripheral blood of non-small cell lung carcinoma patients responding to atezolizumab treatment.
    Fehlings M; Jhunjhunwala S; Kowanetz M; O'Gorman WE; Hegde PS; Sumatoh H; Lee BH; Nardin A; Becht E; Flynn S; Ballinger M; Newell EW; Yadav M
    J Immunother Cancer; 2019 Sep; 7(1):249. PubMed ID: 31511069
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proteogenomic identification of an immunogenic HLA class I neoantigen in mismatch repair-deficient colorectal cancer tissue.
    Hirama T; Tokita S; Nakatsugawa M; Murata K; Nannya Y; Matsuo K; Inoko H; Hirohashi Y; Hashimoto S; Ogawa S; Takemasa I; Sato N; Hata F; Kanaseki T; Torigoe T
    JCI Insight; 2021 Jul; 6(14):. PubMed ID: 34185709
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD103 and CD39 coexpression identifies neoantigen-specific cytotoxic T cells in colorectal cancers with low mutation burden.
    van den Bulk J; van der Ploeg M; Ijsselsteijn ME; Ruano D; van der Breggen R; Duhen R; Peeters KCMJ; Fariña-Sarasqueta A; Verdegaal EME; van der Burg SH; Duhen T; de Miranda NFCC
    J Immunother Cancer; 2023 Feb; 11(2):. PubMed ID: 36792124
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-dose IL-2/CD25 fusion protein amplifies vaccine-induced CD4
    Hernandez R; LaPorte KM; Hsiung S; Santos Savio A; Malek TR
    J Immunother Cancer; 2021 Sep; 9(9):. PubMed ID: 34475132
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Single-cell analysis reveals clonally expanded tumor-associated CD57
    Fehlings M; Kim L; Guan X; Yuen K; Tafazzol A; Sanjabi S; Zill OA; Rishipathak D; Wallace A; Nardin A; Ma S; Milojkovic A; Newell EW; Mariathasan S; Yadav M
    J Immunother Cancer; 2022 Aug; 10(8):. PubMed ID: 35981786
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neoantigen-specific CD4
    Hall MS; Teer JK; Yu X; Branthoover H; Snedal S; Rodriguez-Valentin M; Nagle L; Scott E; Schachner B; Innamarato P; Hall AM; Blauvelt J; Rich CJ; Richards AD; Ceccarelli J; Langer TJ; Yoder SJ; Beatty MS; Cox CA; Messina JL; Abate-Daga D; Mule JJ; Mullinax JE; Sarnaik AA; Pilon-Thomas S
    J Immunother Cancer; 2023 Oct; 11(10):. PubMed ID: 37802604
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of neoantigen-specific T cells and their targets: implications for immunotherapy of head and neck squamous cell carcinoma.
    Ren L; Leisegang M; Deng B; Matsuda T; Kiyotani K; Kato T; Harada M; Park JH; Saloura V; Seiwert T; Vokes E; Agrawal N; Nakamura Y
    Oncoimmunology; 2019; 8(4):e1568813. PubMed ID: 30906664
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study.
    Sun R; Limkin EJ; Vakalopoulou M; Dercle L; Champiat S; Han SR; Verlingue L; Brandao D; Lancia A; Ammari S; Hollebecque A; Scoazec JY; Marabelle A; Massard C; Soria JC; Robert C; Paragios N; Deutsch E; Ferté C
    Lancet Oncol; 2018 Sep; 19(9):1180-1191. PubMed ID: 30120041
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Induction of Neoantigen-Specific Cytotoxic T Cells and Construction of T-cell Receptor-Engineered T Cells for Ovarian Cancer.
    Matsuda T; Leisegang M; Park JH; Ren L; Kato T; Ikeda Y; Harada M; Kiyotani K; Lengyel E; Fleming GF; Nakamura Y
    Clin Cancer Res; 2018 Nov; 24(21):5357-5367. PubMed ID: 29720506
    [No Abstract]   [Full Text] [Related]  

  • 19. Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of melanoma patients.
    Gros A; Parkhurst MR; Tran E; Pasetto A; Robbins PF; Ilyas S; Prickett TD; Gartner JJ; Crystal JS; Roberts IM; Trebska-McGowan K; Wunderlich JR; Yang JC; Rosenberg SA
    Nat Med; 2016 Apr; 22(4):433-8. PubMed ID: 26901407
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Isolation of T-Cell Receptors Specifically Reactive with Mutated Tumor-Associated Antigens from Tumor-Infiltrating Lymphocytes Based on CD137 Expression.
    Parkhurst M; Gros A; Pasetto A; Prickett T; Crystal JS; Robbins P; Rosenberg SA
    Clin Cancer Res; 2017 May; 23(10):2491-2505. PubMed ID: 27827318
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.